Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes.The primary objective of this Phase 1 study is to investigate safety and tolerability of GZR18 in healthy volunteers.
Lead Product(s): Glucagon-like Peptide-1 Analogue
Therapeutic Area: Endocrinology Product Name: GZR18
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary technology BioChaperone®.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: BioChaperone Lispro
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Adocia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: GL-ASP
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2021
Details:
Sciwind Biosciences has completed a phase 1 clinical study of XW003, in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021.
Lead Product(s): XW003
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: LYFE Capital
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 19, 2021
Details:
The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Lead Product(s): Dorzagliatin,Empagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
